Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

Brain

Volumn 139, Issue 4, 2016, Pages 1226-1236

  Palmqvist, Sebastian ^a,b   Mattsson, Niklas ^a,b   Hansson, Oskar ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; amyloid ; CSF A 42; florbetapir; PET

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLORBETAPIR F 18; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); CROSS-SECTIONAL STUDY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; LATERAL ORBITOFRONTAL CORTEX; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDIAL ORBITOFRONTAL CORTEX; MEDIAL PREFRONTAL CORTEX; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; BRAIN CORTEX; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; MIDDLE AGED; PROCEDURES; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CEREBRAL CORTEX; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES;

EID: 84964467855     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww015     Document Type: Article

References (54)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9.
2. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
3. Benaglia T, Chauveau D, Hunter DR, Young D. mixtools: an R package for analyzing finite mixture models. J Stat Softw 2009; 32: 1-29.
4. Biogen. A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects with Mild to Moderate Alzheimer's Disease. In: AD/PD International Conference, Nice, France, 2015.
5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
6. Braak H, Zetterberg H, Del Tredici K, Blennow K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 2013; 126: 631-41.
7. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009; 66: 1557-62.
8. Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012; 6: 502-16.
9. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67: 949-56.
10. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-19.
11. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009; 1: 371-80.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
13. Goedert M. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 2015; 349: 1255555
14. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009; 65: 927-34.
15. Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, et al. Pathways to Alzheimer's disease. J Intern Med 2014; 275: 296-303.
16. Insel PS, Mattsson N, Donohue MC, Mackin RS, Aisen PS, Jack CR Jr, et al. The transitional association between beta-amyloid pathology and regional brain atrophy. Alzheimers Dement 2015; 11: 1171-9.
17. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685-91.
18. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-16.
19. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-28.
20. Jacoby W. Loess: a nonparametric, graphical tool for depicting relationships between variables. Electoral Studies 2000; 19: 577-613.
21. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-9.
22. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med 2012; 53: 378-84.
23. Landau S, Jagust W. Florbetapir processing methods. http://ida.loni.usc.edu Helen Wills Neuroscience Institute, UC Berkeley and Lawrence Berkeley National Laboratory California; 2015.
24. Landau SM, Baker SL, Jagust WJ. Amyloid change early in disease is related to increased glucose metabolism and episodic memory decline. In: Human Amyloid Imaging Meeting, Miami, FL; 2014.
25. Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med 2015; 56: 567-74.
26. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of b-amyloid. Ann Neurol 2013; 74: 826-36.
27. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72: 578-86.
28. Mathis CA, Mason NS, Lopresti BJ, Klunk WE. Development of positron emission tomography beta-amyloid plaque imaging agents. Semin Nucl Med 2012; 42: 423-32.
29. Mattsson N, Insel P, Donohue M, Landau S, Jagust W, Shaw L, et al. Independent information from cerebrospinal fluid b-amyloid and florbetapir imaging in Alzheimer's disease. Brain 2015a; 138 (Pt 3): 772-83.
30. Mattsson N, Insel P, Landau S, Jagust W, Donohue MC, Shaw LM, et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol 2014; 1: 534-43.
31. Mattsson N, Insel PS, Donohue M, Jagust W, Sperling R, Aisen P, et al. Predicting reduction of cerebrospinal fluid beta-amyloid 42 in cognitively healthy controls. JAMA Neurol 2015b; 72: 554-60.
32. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-14.
33. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122-31.
34. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385: 2255-63.
35. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336-45.
36. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014; 71: 1282-9.
37. Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Minthon L, Blennow K; Alzheimer's Disease Neuroimaging Initiative, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer's disease. Neurology 2015; 85: 1240-9.
38. Pfister R, Schwarz K, Carson R, Jancyzk M. Easy methods for extracting individual regression slopes: comparing SPSS, R, and Excel. Tutor. Quant. Methods Psychol. 2013; 9: 72-8.
39. Pietrzak RH, Lim YY, Ames D, Harrington K, Restrepo C, Martins RN, et al. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiol Aging 2015; 36: 1231-8.
40. Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79: 229-36.
41. Sepulcre J, Sabuncu MR, Becker A, Sperling R, Johnson KA. In vivo characterization of the early states of the amyloid-beta network. Brain 2013; 136 (Pt 7): 2239-52.
42. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-13.
43. Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 2014; 84: 608-22.
44. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
45. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011; 3: 111cm33
46. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014; 6: 228fs13
47. Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009; 50: 1464-70.
48. Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, et al. Nonlinear association between cerebrospinal fluid and Florbetapir F-18 beta-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol 2015; 72: 571-81.
49. Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Abeta biomarkers for up to 48 months in ADNI. Acta Neuropathol 2013; 126: 659-70.
50. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-67.
51. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015; 138 (Pt 7): 2020-33.
52. Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012; 135 (Pt 7): 2126-39.
53. Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013; 12: 957-65.
54. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, et al. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement 2011; 7: 133-41.